1. Home
  2. BLNK vs FHTX Comparison

BLNK vs FHTX Comparison

Compare BLNK & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLNK
  • FHTX
  • Stock Information
  • Founded
  • BLNK 2009
  • FHTX 2015
  • Country
  • BLNK United States
  • FHTX United States
  • Employees
  • BLNK N/A
  • FHTX 116
  • Industry
  • BLNK Industrial Specialties
  • FHTX Medicinal Chemicals and Botanical Products
  • Sector
  • BLNK Consumer Discretionary
  • FHTX Health Care
  • Exchange
  • BLNK Nasdaq
  • FHTX Nasdaq
  • Market Cap
  • BLNK 295.1M
  • FHTX 326.4M
  • IPO Year
  • BLNK N/A
  • FHTX 2020
  • Fundamental
  • Price
  • BLNK $3.11
  • FHTX $6.05
  • Analyst Decision
  • BLNK Strong Buy
  • FHTX Buy
  • Analyst Count
  • BLNK 8
  • FHTX 3
  • Target Price
  • BLNK $7.44
  • FHTX $13.00
  • AVG Volume (30 Days)
  • BLNK 5.0M
  • FHTX 143.7K
  • Earning Date
  • BLNK 08-06-2024
  • FHTX 08-02-2024
  • Dividend Yield
  • BLNK N/A
  • FHTX N/A
  • EPS Growth
  • BLNK N/A
  • FHTX N/A
  • EPS
  • BLNK N/A
  • FHTX N/A
  • Revenue
  • BLNK $156,498,000.00
  • FHTX $33,896,000.00
  • Revenue This Year
  • BLNK $23.22
  • FHTX N/A
  • Revenue Next Year
  • BLNK $28.76
  • FHTX $8.63
  • P/E Ratio
  • BLNK N/A
  • FHTX N/A
  • Revenue Growth
  • BLNK 114.36
  • FHTX 64.41
  • 52 Week Low
  • BLNK $2.18
  • FHTX $2.70
  • 52 Week High
  • BLNK $7.25
  • FHTX $9.97
  • Technical
  • Relative Strength Index (RSI)
  • BLNK 51.70
  • FHTX 51.91
  • Support Level
  • BLNK $3.11
  • FHTX $5.62
  • Resistance Level
  • BLNK $3.75
  • FHTX $6.98
  • Average True Range (ATR)
  • BLNK 0.21
  • FHTX 0.58
  • MACD
  • BLNK 0.02
  • FHTX 0.09
  • Stochastic Oscillator
  • BLNK 49.57
  • FHTX 51.13

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns majority revenue from U.S.A.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: